

Online Resource 1:

Data input to the base case model

Journal name: The European Journal of Health Economics.

Article title: Survival and costs of colorectal cancer treatment and effects of changing treatment strategies - a model approach.

Authors: Paal Joranger, Arild Nesbakken, Halfdan Sorbye, Geir Hoff, Arne Oshaug, Eline Aas.

Corresponding author: Paal Joranger, Norway/Faculty of Health Sciences, OsloMet – Oslo Metropolitan University, NO-0130 Oslo, Norway. E-mail: pal.joranger@oslomet.no

Table 1 Frequency per-patient and values per-unit for primary treatments used in the base case model analysis. The frequencies show how many times an average patient with a certain diagnosis receives the listed treatment (see also the text). Costs are in 2011 €

Treatment first year after primary diagnosis (DRG, medical: M, surgical: S)	Row no.	Primary treatment stage				Unit cost (€)	Source
		I	II	III	IV		
Resection of primary tumour							
Colon resection, w (148, S)	1	.210	.280	.458	.443	23,913	OUS
Colon resection, n (149, S)	2	.300	.401	.192	.023	11,688	OUS
Rectal resection, w (146, S)	3	.267	.174	.218	.120	18,546	OUS
Rectal resection, n (147, S)	4	.221	.145	.119	.0	12,486	OUS
Non-resection surgery							
Endoscopic therapy colon; closure stoma, w (152, S)	5	.0	.0	.045	.026	9539	NPR
Endoscopic therapy colon; closure stoma, n (153, S)	6	.036	.036	.090	.026	6758	NPR
Endoscopic therapy rectum; TEM, w (157, S)	7	.0	.0	.0	.101	5519	OUS
Endoscopic therapy rectum; TEM, n (158, S)	8	.0	.0	.0	.034	2748	OUS
GI obstruction, w (180, S)	9	.0	.0	.0	.044	3939	OUS
GI obstruction, n (181, S)	10	.0	.0	.0	.015	2140	OUS
Endoscopic/other treatment							
Digestive malignancy, w (172, M)	11	.0	.107	.493	1.526	7526	NPR
Digestive malignancy, n (173, M)	12	.0	.0	.164	.184	4409	NPR
Aftercare and rehabilitation (465)	13	.0	.0	.030	.553	6207	NPR
Endoscopic insertion of stent to Gastro; tract, short therapy (703O)	14	.0	.0	.0	.008	1310	OUS
Treatment for metastasis							
<i>Resection</i>							
Liver metastasis resec., w (191B, S)	15	.0	.0	.0	.125	26,528	Source a
Lung metastasis resection (75, S)	16	.0	.0	.0	.019	18,968	Source b
<i>Non-surgical supportive treatment and care</i>							
Liver metastasis (203, M)	17	.0	.0	.0	.188	6468	NPR, exp
Lung metastasis (82, M)	18	.0	.0	.0	.075	7664	NPR, exp
Chemo- and radiotherapy							
Radiotherapy (409E, M)	19	.033	.075	.147	.056	645 *	Source c, exp
Palliative chemotherapy (M)	20	.0	.0	.0	.610	20,183 †	Source d
Adjuvant chemotherapy (M)	21	.0	.054	.535	.05	8677/7494	Source e

Note: w=with complications or co-morbidities; n=without complications or co-morbidities; exp=Expert opinion; OUS=observational study at Oslo University Hospital – Aker; NPR=National Patient Register based on data organized by Aas (1); *=costs per visit at hospital for radiotherapy; †=costs in the first year of palliative treatment; Source a=(2), (20), (3), (4); Source b=(2), (4); Source c=(5, 6), exp.; Source d=(5, 7-10); Source e=(5, 7-10). Reproduced from (11) with the kind permission of Sage publishers.

References

1. Aas E. Cost-effectiveness of screening for colorectal cancer with once-only flexible sigmoidoscopy and faecal occult blood test. Oslo University, Health Economics Research Programme; 2009.

2. Körner H, Søreide K, Stokkeland P, Søreide J. Systematic follow-up after curative surgery for colorectal cancer in Norway: A population-based audit of effectiveness, costs, and compliance. *Journal of Gastrointestinal Surgery*. 2005;9(3):320-8.
3. Søreide J A, Eiriksson K, Sandvik O, Viste A, Horn A, Johnsen G, et al. Kirurgisk behandling av levermetastaser fra kolorektal kreft. *Tidsskr Nor Legeforen* 2008;128(1):50-3.
4. Kobayashi H, Mochizuki H, Sugihara K, Morita T, Kotake K, Teramoto T, et al. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: A multicenter study. *Surgery*. 2007;141(1):67-75.
5. Delcò F, Egger R, Bauerfeind P, Beglinger C. Hospital health care resource utilization and costs of colorectal cancer during the first 3-year period following diagnosis in Switzerland. *Alimentary Pharmacology & Therapeutics*. 2005;21(5):615-22.
6. Sorbye H, Pfeiffer P, Cavalli-Björkman N, Qvortrup C, Holsen MH, Wentzel-Larsen T, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. *Cancer*. 2009;115(20):4679-87.
7. van Steenbergen L, Elferink M, Krijnen P, Lemmens V, Siesling S, Rutten H, et al. Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989-2006. *Annals of Oncology*. 2010;21(11):2206-12.
8. Lemmens V, de Haan N, Rutten H, Martijn H, Loosveld O, Roumen R, et al. Improvements in population-based survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, 1992–2008. *Clinical and Experimental Metastasis*. 2011;28(3):283-90.
9. Khattak MA, Townsend AR, Beeke C, Karapetis CS, Luke C, Padbury R, et al. Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. *European Journal of Cancer*. 2012;48(9):1293-8.
10. Jacob S, Ng W, Asghari R, Delaney GP, Barton MB. Estimation of an optimal chemotherapy utilisation rate for colon cancer: An evidence-based benchmark for cancer care. *European Journal of Cancer*. 2009;45(14):2503-9.
11. Joranger P, Nesbakken A, Hoff G, Sorbye H, Oshaug A, Aas E. Modeling and validating the cost and clinical pathway of colorectal cancer. *Medical Decision Making*. 2014.